Keyphrases
Obesity
100%
Clinical Practice Guidelines
100%
Pharmacological Intervention
100%
Extended Release
75%
Lifestyle Intervention
75%
Guideline Panel
75%
Lack of Response
50%
Semaglutide 2.4 Mg
50%
Liraglutide 3.0 Mg
50%
Phentermine
50%
Obesity Management
50%
Pharmacological Management
50%
Superabsorbent Hydrogel
50%
Orlistat
50%
Phentermine-topiramate
50%
Diethylpropion
50%
Naltrexone-bupropion
50%
Improved Outcomes
25%
Pharmacological Therapy
25%
Effective Treatment
25%
Treatment Options
25%
Pharmacotherapy
25%
Clinical Practice
25%
Assessment Development
25%
Evaluation Assessment
25%
Patient-centered Outcomes
25%
Long-term Management
25%
Evaluation Framework
25%
Knowledge Gaps
25%
Associated Complications
25%
Assessment Framework
25%
Development Framework
25%
Safe Treatment
25%
Obesity Risk
25%
Obesity Body Mass Index
25%
Grading of Recommendations
25%
Obesity-related Complications
25%
Methodologists
25%
Content Expert
25%
Multidisciplinary Panel
25%
American Gastroenterological Association
25%
Extended-release Naltrexone
25%
Evidence to Decision Framework
25%
Medicine and Dentistry
Obesity
100%
Lifestyle Intervention
75%
Drug Therapy
50%
Bupropion
50%
Semaglutide
50%
Amfepramone
50%
Phentermine
50%
Orlistat
50%
Phentermine/Topiramate
50%
Naltrexone
50%
Liraglutide
50%
Body Mass Index
25%
Methodologist
25%
Nursing and Health Professions
Practice Guideline
100%
Obesity
66%
Hydrogel
33%
Obesity Management
33%
Tetrahydrolipstatin
33%
Drug Therapy
33%
Bupropion
33%
Semaglutide
33%
Phentermine/Topiramate
33%
Naltrexone
33%
Phentermine
33%
Liraglutide
33%
Amfepramone
33%
Physician
16%
Clinical Practice
16%
Body Mass
16%
Methodologist
16%
Pharmacology, Toxicology and Pharmaceutical Science
Obesity
100%
Pharmacotherapy
50%
Naltrexone
50%
Bupropion
50%
Semaglutide
50%
Tetrahydrolipstatin
50%
Liraglutide
50%
Phentermine/Topiramate
50%
Phentermine
50%
Amfepramone
50%